-

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.

Panel Discussion Details:

Speaker: Robin Taylor, Ph.D., Chief Commercial Officer

Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’

Date: 02/28/2025

Time: 1:00-2:00 p.m. ET

Location: New York City, NY

This event is for in-person participants only. Contact B. Riley for information on attending the conference.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Contacts

Investors
917-362-1370
investor@agenusbio.com

Media
510-323-5188
communications@agenusbio.com

Industry:

Agenus Inc.

NASDAQ:AGEN
Release Versions
English

Contacts

Investors
917-362-1370
investor@agenusbio.com

Media
510-323-5188
communications@agenusbio.com

More News From Agenus Inc.

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026. The discussion will be moderated by Michael G. King, Jr., Senior Biotechnology Analyst and will focus on the development of botensilimab (BOT) and ba...

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The...

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, given before surgery...
Back to Newsroom